Home Markets Leucine Rich Repeat Serine/Threonine Protein Kinase 2 Drug

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 Drug

142
SHARE

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 Pipeline and Therapeutics Development H1 2017 provides comprehensive information on the therapeutics under development for Leucine Rich Repeat Serine/Threonine Protein Kinase 2, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Companies Involved in Leucine Rich Repeat Serine/Threonine Protein Kinase 2 Development are Arrien Pharmaceuticals LLC, D. Western Therapeutics Institute Inc, Denali Therapeutics Inc, H. Lundbeck A/S, Lead Discovery Center GmbH, Merck & Co Inc, Novartis AG, Oncodesign SA, Origenis GmbH, Pfizer Inc

The Leucine Rich Repeat Serine/Threonine Protein Kinase 2 pipeline guide also reviews of key players involved in therapeutic development for Leucine Rich Repeat Serine/Threonine Protein Kinase 2 and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 5 and 1 respectively.

Sample copy is available at https://www.marketinsightsreports.com/reports/062215761/leucine-rich-repeat-serine-threonine-protein-kinase-2-dardarin-or-lrrk2-or-ec-2-7-11-1-pipeline-review-h1-2017/inquiry

Scope of this report:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Leucine Rich Repeat Serine/Threonine Protein Kinase 2. The pipeline guide reviews pipeline therapeutics for Leucine Rich Repeat Serine/Threonine Protein Kinase 2 by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Leucine Rich Repeat Serine/Threonine Protein Kinase 2 therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Leucine Rich Repeat Serine/Threonine Protein Kinase 2 therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Leucine Rich Repeat Serine/Threonine Protein Kinase 2.
  • This research report can: Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Leucine Rich Repeat Serine/Threonine Protein Kinase 2. Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Leucine Rich Repeat Serine/Threonine Protein Kinase 2 pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Browse Full Report at: https://www.marketinsightsreports.com/reports/062215761/leucine-rich-repeat-serine-threonine-protein-kinase-2-dardarin-or-lrrk2-or-ec-2-7-11-1-pipeline-review-h1-2017

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) – Leucine-rich repeat kinase 2 (LRRK2) is an enzyme encoded by the PARK8 gene. It plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose 6 phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent manner together with RAB29. It regulates neuronal process morphology in the intact central nervous system.

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) pipeline Target constitutes close to 16 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Preclinical and Discovery stages are 8 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Ophthalmology and Respiratory which include indications Parkinson’s Disease, Neurodegenerative Diseases, Glaucoma and Lung Disease.

The latest report Leucine Rich Repeat SerineThreonine Protein Kinase 2 – Pipeline Review, H1 2017, outlays comprehensive information on the Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

LEAVE A REPLY

Please enter your comment!
Please enter your name here